Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients

Li Chen(University of Macau), Shunchang Jiao(Chinese PLA General Hospital), Bo Wei(People's Liberation Army No. 150 Hospital), Lixin Wei(Shanghai Cancer Institute), Jing Yuan(Sun Yat-sen University), Yalin Han(Chinese People's Liberation Army), Rui Qin(Regeneron (United States)), Qian Wu(University of Connecticut), Baoqing Jia(Chinese PLA General Hospital), Guanghai Dai(Chinese PLA General Hospital), Yan Shi(Hebei Provincial Center for Disease Control and Prevention)
Medical Oncology
August 13, 2014
10.1007/s12032-014-0159-5
Cited by 29

Related Papers

Long-Term Survival After Pancreatoduodenectomy for Pancreatic Adenocarcinoma
|Annals of Surgery|2008|461
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene
|Cancer Cell|2004|379
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
|JAMA|2017|357
Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells
|Cancer Research|2009|165